Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

NCT05965427

CompletedN/A

Sponsor: NEAT ID Foundation

Conditions: Monkeypox, HIV Coinfection

Interventions: No intervention

Countries: France, Poland, Spain, United Kingdom

This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also aims to identify risk factors for specific Mpox outcomes.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Diagnosis of MPX was more than 90 days prior to data collection
* Confirmed MPX infection by documented PCR testing of lesions between 1st May 2022 to 1st December 2023
* At least 18 years of age
* Cases (PLWHIV + MPX) i) Documented HIV-1 infection
* Cases (PrEP users + MPX) i) Attended a clinic to receive PrEP

Exclusion Criteria:

* MPX diagnosed based on clinical criteria only
* MPX diagnosis was within the last 90 days
Locations (9)
  • Paris, France
  • Paris, France
  • Warsaw, Poland
  • Barcelona, Spain
  • Barcelona, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Madrid, Spain
  • London, United Kingdom